Drugs / RLD2106
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05450601 Comparator | Sep 2022 → Dec 2023 | hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RLD2106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05450601 ↗ |
| Route | Oral | “Take once daily for 2 weeks orally” NCT05450601 ↗ |